Cancer Biology & Medicine最新文献

{"title":"Circulating cell-free mtDNA as a new biomarker for cancer detection and management.","authors":"Fan Peng, Siyuan Wang, Zehui Feng, Kaixiang Zhou, Huanqin Zhang, Xu Guo, Jinliang Xing, Yang Liu","doi":"10.20892/j.issn.2095-3941.2023.0280","DOIUrl":"10.20892/j.issn.2095-3941.2023.0280","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2023-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10884534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41221487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Next-generation antibody-drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer.","authors":"Lei-Jie Dai, Yu-Wei Li, Ding Ma, Zhi-Ming Shao, Yi-Zhou Jiang","doi":"10.20892/j.issn.2095-3941.2023.0286","DOIUrl":"10.20892/j.issn.2095-3941.2023.0286","url":null,"abstract":"The concept of antibody–drug conjugations (ADCs) can be tracked back to the early 20 th century when the renowned immunologist, Paul Ehrlich, proposed the idea of a “magic bullet”, which utilizes ADCs for targeted destruction of micro-organisms and tumor cells 1 . After nearly one century of development, ADCs have emerged as a rather promising approach in the treatment of cancer, especially breast cancer, which is the most common malignant tumor in women 2 . Human epidermal growth factor receptor 2 ( HER2 ), also known as Erb-B2 receptor tyrosine kinase 2 ( ERBB2 ), is a crucial molecular classifier for breast cancer. The HER2 status is determined using immunohistochemistry (IHC) and in situ hybridization (ISH) in pathology laboratories. Approximately 15% of breast cancer patients exhibit HER2 overexpression and are thus defined as HER2-positive breast cancers. HER2 was a pivotal driver and therapeutic target in these patients 3 . HER2 is not considered to be a driving factor and is conventionally not targetable for breast cancers that display low-to-moderate HER2 expression (usually referred to as HER2-low breast cancers) 4 . The emergence of next-generation ADCs, represented by trastuzumab deruxtecan [T-DXd (also called DS-8201)], has revolutionized the precise classification and treat-ment of HER2-expressing breast cancer, including both HER2-overexpressing HER2-positive breast cancers and HER2-moderately expressed","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618949/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41221491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic medicine in clinical practice: national genomic medicine program in Japan.","authors":"Yayoi Ando, Tatsunori Shimoi, Tatsuya Suzuki, Hideki Ueno, Natsuko Okita, Kenichi Nakamura","doi":"10.20892/j.issn.2095-3941.2023.0219","DOIUrl":"10.20892/j.issn.2095-3941.2023.0219","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10875283/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41221489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting endoplasmic reticulum stress signaling in ovarian cancer therapy.","authors":"Tianqing Yan,&nbsp;Xiaolu Ma,&nbsp;Lin Guo,&nbsp;Renquan Lu","doi":"10.20892/j.issn.2095-3941.2023.0232","DOIUrl":"10.20892/j.issn.2095-3941.2023.0232","url":null,"abstract":"<p><p>The endoplasmic reticulum (ER), an organelle present in various eukaryotic cells, is responsible for intracellular protein synthesis, post-translational modification, and folding and transport, as well as the regulation of lipid and steroid metabolism and Ca²⁺ homeostasis. Hypoxia, nutrient deficiency, and a low pH tumor microenvironment lead to the accumulation of misfolded or unfolded proteins in the ER, thus activating ER stress (ERS) and the unfolded protein response, and resulting in either restoration of cellular homeostasis or cell death. ERS plays a crucial role in cancer oncogenesis, progression, and response to therapies. This article reviews current studies relating ERS to ovarian cancer, the most lethal gynecologic malignancy among women globally, and discusses pharmacological agents and possible targets for therapeutic intervention.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41221492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microbiome changes in esophageal cancer: implications for pathogenesis and prognosis.","authors":"Yi Li, Bing Wei, Xia Xue, Hongle Li, Jun Li","doi":"10.20892/j.issn.2095-3941.2023.0177","DOIUrl":"10.20892/j.issn.2095-3941.2023.0177","url":null,"abstract":"<p><p>Esophageal cancer (EC) is an aggressive malignancy with a poor prognosis. Various factors, including dietary habits, and antacid and antibiotic use, have been shown to influence the esophageal microbiome. Conversely, enrichment and diversity of the esophageal microbiome can also impact its function. Recent studies have revealed prevalent changes in the esophageal microbiome among patients with EC, thus suggesting the potential contribution of the esophageal microbiome to EC development. Additionally, distinct microbiome compositions have been observed in patients with different responses to radiotherapy and chemotherapy, indicating the role of the esophageal microbiome in modulating treatment outcomes. In this review, we have examined previous studies on the esophageal microbiome in healthy individuals and patients with EC or other esophageal diseases, with a focus on identifying microbial communities associated with EC pathogenesis and prognosis. Understanding the role of the microbiome in EC may aid in early detection and optimized treatment strategies, ultimately leading to better outcomes for patients.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2023-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10884538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41221490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging roles of plasmacytoid dendritic cell crosstalk in tumor immunity.","authors":"Leilei Yang,&nbsp;Songya Li,&nbsp;Liuhui Chen,&nbsp;Yi Zhang","doi":"10.20892/j.issn.2095-3941.2023.0241","DOIUrl":"10.20892/j.issn.2095-3941.2023.0241","url":null,"abstract":"<p><p>Plasmacytoid dendritic cells (pDCs) are a pioneer cell type that produces type I interferon (IFN-I) and promotes antiviral immune responses. However, they are tolerogenic and, when recruited to the tumor microenvironment (TME), play complex roles that have long been a research focus. The interactions between pDCs and other components of the TME, whether direct or indirect, can either promote or hinder tumor development; consequently, pDCs are an intriguing target for therapeutic intervention. This review provides a comprehensive overview of pDC crosstalk in the TME, including crosstalk with various cell types, biochemical factors, and microorganisms. An in-depth understanding of pDC crosstalk in TME should facilitate the development of novel pDC-based therapeutic methods.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41221488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent research hotspots in sequencing and the pancreatic neuroendocrine tumor microenvironment.","authors":"Junfeng Xu,&nbsp;Wuhu Zhang,&nbsp;Xin Lou,&nbsp;Zeng Ye,&nbsp;Yi Qin,&nbsp;Jie Chen,&nbsp;Xiaowu Xu,&nbsp;Xianjun Yu,&nbsp;Shunrong Ji","doi":"10.20892/j.issn.2095-3941.2023.0284","DOIUrl":"10.20892/j.issn.2095-3941.2023.0284","url":null,"abstract":"Multiple endocrine neoplasia 1 (MEN1) syndrome, a disease arising from a genetic predisposition to tumor development caused by MEN1 loss-of-function mutations, is characterized by the combined occurrence of neuroendocrine tumors in multiple human organs. With advances in diagnostic technologies and improvements in living standards, the detection rate of sporadic pancreatic neuroendocrine tumors (PanNETs) has recently increased. Clinical research and treatment approaches for PanNETs have made remarkable progress. However, the heterogeneity and the mechanisms underlying PanNET malignancy have not yet been fully elucidated. Recurrence and metastasis remain major issues faced by clinicians. In-depth research on the biological behavior of PanNETs is necessary to improve treatment efficacy and precision. With molecular biology advances, new basic research findings may have potential clinical translational value for PanNETs 1,2 . Specifically, advances in high-throughput sequencing technologies have greatly","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41158867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapy for multiple myeloma: new chances and hope.","authors":"Jingyu Xu,&nbsp;Gang An,&nbsp;Lugui Qiu","doi":"10.20892/j.issn.2095-3941.2023.0258","DOIUrl":"10.20892/j.issn.2095-3941.2023.0258","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41173648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liquid-liquid phase separation in DNA double-strand break repair.","authors":"Jia Chen,&nbsp;Jie Shi,&nbsp;Jian Zheng,&nbsp;Yunlong Wang,&nbsp;Xiangbo Wan","doi":"10.20892/j.issn.2095-3941.2023.0252","DOIUrl":"https://doi.org/10.20892/j.issn.2095-3941.2023.0252","url":null,"abstract":"DNA repair factors function through spatiotemporal condensation and dissolution at DNA double-strand breaks (DSBs). Recent advances have indicated that some DSB repair factors undergo liquid-liquid phase separation (LLPS) and show droplet-like properties, as well as dynamic material exchange. Importantly, LLPS regulates various biological processes, and aberrant LLPS is involved in the pathologic progression of various diseases. In addition, the phenotype of dynamic condensation and dissolution of DNA repair factors during DSB repair presents properties to LLPS. Significantly, RNA, poly (ADP-ribose) [PAR], and post-transcription modification (PTM), such as phosphorylation, ubiquitination, and methylation, are thought to contribute to the LLPS of DSB repair factors. From the perspective of LLPS function during DSB, DNA repair factors may undergo LLPS to act in DSB sensing and DNA damage repair signal transduction, participate in homologous recombination (HR)- and non-homologous end-joining (NHEJ)- mediated DSB repair, and regulate downstream responding pathways. Based on these findings, researchers have focused","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41173647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer.","authors":"Xiaohui Wang,&nbsp;Wei Qiu,&nbsp;Haoyu Liu,&nbsp;Min He,&nbsp;Wei He,&nbsp;Zhan Li,&nbsp;Zhiqiang Wu,&nbsp;Xiang Xu,&nbsp;Ping Chen","doi":"10.20892/j.issn.2095-3941.2023.0033","DOIUrl":"https://doi.org/10.20892/j.issn.2095-3941.2023.0033","url":null,"abstract":"<p><strong>Objective: </strong>CAR-T/NK cells have had limited success in the treatment of solid tumors, such as colorectal cancer (CRC), in part because of the heterogeneous nature of tumor-associated antigens that lead to antigen-negative relapse after the initial response. This barrier might be overcome by enhancing the recruitment and durability of endogenous immune cells.</p><p><strong>Methods: </strong>Immunohistochemistry and flow cytometry were used to assess the expression of CD133 antigen in tissue microarrays and cell lines, respectively. Retroviral vector transduction was used to generate CBLB502-secreting CAR133-NK92 cells (CAR133-i502-NK92). The tumor killing capacity of CAR133-NK92 cells <i>in vitro</i> and <i>in vivo</i> were quantified <i>via</i> LDH release, the RTCA assay, and the degranulation test, as well as measuring tumor bioluminescence signal intensity in mice xenografts.</p><p><strong>Results: </strong>We engineered CAR133-i502-NK92 cells and demonstrated that those cells displayed enhanced proliferation (9.0 × 10⁴ cells <i>vs</i>. 7.0 × 10⁴ cells) and specific anti-tumor activities <i>in vitro</i> and in a xenogeneic mouse model, and were well-tolerated. Notably, CBLB502 secreted by CAR133-i502-NK92 cells effectively activated endogenous immune cells. Furthermore, in hCD133+/hCD133- mixed cancer xenograft models, CAR133-i502-NK92 cells suppressed cancer growth better than the counterparts (<i>n</i> = 5, <i>P</i> = 0.0297). Greater T-cell infiltration was associated with greater anti-tumor potency (<i>P</i> < 0.0001).</p><p><strong>Conclusions: </strong>Armed with a CBLB502 TLR5 agonist, CAR133-NK92 cells were shown to be capable of specifically eliminating CD133-positive colon cancer cells in a CAR133-dependent manner and indirectly eradicating CD133-negative colon cancer cells in a CBLB502-specific endogenous immune response manner. This study describes a novel technique for optimizing CAR-T/NK cells for the treatment of antigenically-diverse solid tumors.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41170387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}